Open company graph database — free web & API
Login

Novo Nordisk Pharma Co., Ltd.

ノボ ノルディスク ファーマ株式会社
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
0
§01

Basic information

BASIC
Head office
Chief executive
Keisuke Kotani
Capital
2,104,050,000 JPY (21 100 millionJPY)
Employees (non-consolidated)
Employees (consolidated)
Start date
1980-06-20
End date
§02

Websites

1 DOMAINS
§03

Business

3
Innovative discovery and development of pharmaceuticalsSourcesProviding these pharmaceuticals to patients worldwideSourcesDiabetes treatment, obesity treatment, hemophilia treatment, and growth hormone therapySources
§04

Related companies

0 COMPANIES

—

§05

Network

NETWORK
Drag to move · click to open
§06

History

41 EVENTS

The brothers, former employees of Nordisk, Harald Pedersen and Torvald Pedersen, founded the Novo Therapeutics Institute. Novo and Nordisk engaged in fierce competition until they merged in 1989 to form Novo Nordisk A/S.Sources

Former Novo Nordisk employees Harald Pedersen and Torvald Pedersen, brothers, founded Novo Therapeutics Research Institute.Sources

Established Steno Memorial Hospital.Sources

Established Vidor Hospital.Sources

In 1946, NPH (Neutral Protamine Hagedorn) insulin was developed and quickly became the majority of long‑acting insulin preparations used worldwide. The introduction of NPH reduced the number of injections needed for people with diabetes. The product was named after Hans Christian Hagedorn, who discovered the long‑acting effect of protamine on insulin.Sources

Developed NPH (Neutral Protamine Hagedorn) insulin.Sources

In 1951, Harald Pedersen and Torvald Pedersen established the Novo Foundation.Sources

Harald Pedersen and Torvald Pedersen established the Novo Foundation.Sources

Novo Nordisk Japan signed a sales agreement for insulin with Yamanoi Pharmaceutical.Sources

Novo Pharmaceutical released its first semi‑synthetic human insulin preparation.Sources

Novo Pharmaceutical began its own sales system.Sources

Novo Pharmaceutical releases pen-type insulin injector and dedicated insulin cartridge formulation, along with dedicated injection needles.Sources

Releases vial formulation.Sources

Novo and Nordisk engaged in fierce competition until they merged in 1989 to form Novo Nordisk A/S.Sources

Novo Nordisk Japan releases recombinant human growth hormone formulation.Sources

Novo and Nordisk merged to form Novo Nordisk A/S.Sources

Both foundations merged to become the Novo Nordisk Foundation.Sources

Novo Pharmaceutical and Novo Nordisk merge to form Novo Nordisk Pharma Co., Ltd.Sources

Consolidates sales company under Yamanoi Pharmaceutical.Sources

In 1992, the two hospitals merged to establish the Steno Diabetes Center.Sources

Releases recombinant human insulin formulation.Sources

Both hospitals merged to establish the Steno Diabetes Center.Sources

Releases pen-type insulin injector with dial setting for dosage per unit.Sources

Releases pen-type injector for human growth hormone and dedicated cartridge formulation.Sources

In 2001, in response to a patent dispute that arose in South Africa, Novo Nordisk developed a long‑term strategy to support access to treatment in the world’s poorest countries. The strategy included the establishment of the World Diabetes Foundation (2002) and the Novo Nordisk Hemophilia Foundation (2005), as well as differentiated pricing policies for insulin targeting developing countries.Sources

In response to a patent dispute arising in South Africa, Novo Nordisk devised a long-term strategy to support access to treatment in the world's poorest countries.Sources

In 2002, the World Diabetes Foundation was established.Sources

Established the World Diabetes Foundation.Sources

In 2005, the Novo Nordisk Hemophilia Foundation was established.Sources

In 2005, more than ten years after the introduction of the "Novo Nordisk Way of Management," which set a vision and policy applicable to all employees worldwide, the company introduced the "Novo Nordisk Way," emphasizing its history and values.Sources

Established the Novo Nordisk Hemophilia Foundation.Sources

In 2011, Novo Nordisk introduced its values – the Novo Nordisk Way.Sources

More than ten years after introducing the "Novo Nordisk Way of Management"—a vision and policy applicable to all employees worldwide—Novo Nordisk introduced the "Novo Nordisk Way" to emphasize the company's history and values.Sources

In 2014, as a public‑private partnership addressing the impact of urban life on the rise of chronic diseases, the company launched the "Cities Changing Diabetes" program, focusing on prevention.Sources

As a public-private partnership addressing the impact of urban living on the rise of chronic diseases, we launched the "Cities Changing Diabetes" program, focusing on prevention of diabetes spread in cities.Sources

Novo Nordisk celebrates its 100th anniversary, a milestone and opportunity, renewing its commitment to drive transformation toward a healthier world for the current and next generations.Sources

First oral GLP-1 therapy targeting type 2 diabetes.Sources

In 2021, the company expanded its partnership with UNICEF, working to create healthier environments for children and address childhood overweight and obesity.Sources

Expanding our business in partnership with UNICEF, we are working to prevent childhood overweight and obesity by creating healthier environments for children.Sources

2023 – Driving transformation over a centurySources

Novo Nordisk celebrates its 100th anniversary, a remarkable milestone and opportunity, reaffirming its commitment to drive transformation toward a healthier world for current and future generations.Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑